Author + information
- Received June 26, 1989
- Revision received December 6, 1989
- Accepted December 20, 1989
- Published online May 1, 1990.
- Killian Robinson, MRCP1,
- Michael P. Frenneaux, MRCP1,
- Benjamin Stockins, MD1,
- George Karatasakis, MD1,
- Jan D. Poloniecki, DPhil1 and
- William J. Mckenna, MD, FACC*,1
- ↵*Address for reprints: William J. McKenna, MD, Department of Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, England.
The clinical outcome of 52 consecutive patients with hypertrophic cardiomyopathy who developed paroxysmal (<1 week) or established (≥l week) atrial fibrillation between 1960 and 1985 was examined retrospectively and compared with that of a matched group of patients with hypertrophic cardiomyopathy and sinus rhythm. Follow-up study until death or the present ranged from 6 months to 24 years (median 11 years) from diagnosis and from 6 months to 22 years (median 7 years) from the onset of atrial fibrillation. Atrial fibrillation was present in 6 patients at the time of diagnosis, whereas it developed subsequently in 46. The acute onset of arrhythmia was associated with a change in symptoms in 41 (89%) of the 46. After initial treatment of acute atrial fibrillation, sinus rhythm was restored in 29 (63%) of the 46 patients; 43 (93%) of the 46 returned to their original symptom class. Stepwise logistic regression revealed that shorter duration of arrhythmia and amiodarone therapy were the most powerful predictors of return to sinus rhythm. Sinus rhythm was maintained during a median follow-up period of 5.5 years in 22 of the 29 patients in whom it was restored after initial therapy.
During follow-up study, 25 of the 52 patients were treated with conventional therapy alone and 7 with amiodarone alone. Amiodarone therapy was associated with maintenance of sinus rhythm, fewer alterations in drug therapy, fewer embolic episodes and fewer attempted direct current cardioversions (during a shorter follow-up period). The remaining 20 patients initially received conventional therapy but were not well controlled and were switched to amiodarone (median 200 mg/day), after which there were fewer alterations in drug therapy and fewer direct current cardioversions during a similar follow-up period.
There were 19 disease-related deaths. Estimated probability of surviving 5,10,15 and 20 years after the diagnosis of hypertrophic cardiomyopathy was 0.86, 0.71, 0.65 and 0.50 and was similar in a concurrent group of 122 patients with hypertrophic cardiomyopathy who remained in sinus rhythm (0.92, 0.82, 0.71 and 0.41), respectively.
- Received June 26, 1989.
- Revision received December 6, 1989.
- Accepted December 20, 1989.
- American College of Cardiology Foundation